These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 7850057)
41. Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients. Tampellini M; Berruti A; Bitossi R; Gorzegno G; Alabiso I; Bottini A; Farris A; Donadio M; Sarobba MG; Manzin E; Durando A; Defabiani E; De Matteis A; Ardine M; Castiglione F; Danese S; Bertone E; Alabiso O; Massobrio M; Dogliotti L Breast Cancer Res Treat; 2006 Aug; 98(3):241-8. PubMed ID: 16670941 [TBL] [Abstract][Full Text] [Related]
42. Locoregional recurrence after management of carcinoma breast. Farid G; Rasool MI J Coll Physicians Surg Pak; 2005 Apr; 15(4):218-20. PubMed ID: 15857594 [TBL] [Abstract][Full Text] [Related]
44. Evaluation of CA 15-3 tumor marker in the diagnosis of breast cancer. A pilot study. Wojtacki J; Dziewulska-Bokiniec A; Skokowski J; Ciesielski D Neoplasma; 1994; 41(4):213-6. PubMed ID: 7935994 [TBL] [Abstract][Full Text] [Related]
45. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers. Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752 [TBL] [Abstract][Full Text] [Related]
46. CA15-3: its relationship to clinical stage and progression to metastatic disease in breast cancer. Kerin MJ; McAnena OJ; O'Malley VP; Grimes H; Given HF Br J Surg; 1989 Aug; 76(8):838-9. PubMed ID: 2765841 [TBL] [Abstract][Full Text] [Related]
47. Is immediate postoperative CA15.3 assay a predictive marker of early postoperative recurrence of carcinoma breast? Sarkar DK; Panda N; Biswas S; Saha ML; Majumder A J Indian Med Assoc; 2012 Mar; 110(3):146-7. PubMed ID: 23029943 [TBL] [Abstract][Full Text] [Related]
48. The prognostic role of preoperative and (early) postoperatively change in CA15.3 serum levels in a single hospital cohort of primary operable breast cancers. Brouckaert O; Laenen A; Wildiers H; Floris G; Moerman P; Van Limbergen E; Vergote I; Billen J; Christiaens MR; Neven P Breast; 2013 Jun; 22(3):254-62. PubMed ID: 23566558 [TBL] [Abstract][Full Text] [Related]
49. Does the pre-operative value of serum CA15-3 correlate with survival in breast cancer? Velaiutham S; Taib NA; Ng KL; Yoong BK; Yip CH Asian Pac J Cancer Prev; 2008; 9(3):445-8. PubMed ID: 18990019 [TBL] [Abstract][Full Text] [Related]
50. [The significance of screening studies for the early detection of metastases in curatively operated breast carcinoma]. Fenner D; Hofmann V Schweiz Med Wochenschr; 1988 Feb; 119(5):156-9. PubMed ID: 3238401 [TBL] [Abstract][Full Text] [Related]
51. The significance of CA15-3 in breast cancer patients and its relationship to HER-2 receptor status. Hashim ZM Int J Immunopathol Pharmacol; 2014; 27(1):45-51. PubMed ID: 24674678 [TBL] [Abstract][Full Text] [Related]
52. Rapid and label-free detection of breast cancer biomarker CA15-3 in clinical human serum samples with optofluidic ring resonator sensors. Zhu H; Dale PS; Caldwell CW; Fan X Anal Chem; 2009 Dec; 81(24):9858-65. PubMed ID: 19911811 [TBL] [Abstract][Full Text] [Related]
53. The value of CA15-3 in diagnosis, prognosis and treatment response in women with breast cancer. Ali HQ; Mahdi NK; Al-Jowher MH J Pak Med Assoc; 2013 Sep; 63(9):1138-41. PubMed ID: 24601193 [TBL] [Abstract][Full Text] [Related]
54. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer. Hayes DF; Zurawski VR; Kufe DW J Clin Oncol; 1986 Oct; 4(10):1542-50. PubMed ID: 2428949 [TBL] [Abstract][Full Text] [Related]
55. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Nicolini A; Ferrari P; Sagripanti A; Carpi A Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888 [TBL] [Abstract][Full Text] [Related]
56. Tumour marker CA15-3: possible uses in the routine management of breast cancer. Tomlinson IP; Whyman A; Barrett JA; Kremer JK Eur J Cancer; 1995 Jun; 31A(6):899-902. PubMed ID: 7646918 [TBL] [Abstract][Full Text] [Related]
57. CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients. Incoronato M; Mirabelli P; Catalano O; Aiello M; Parente C; Soricelli A; Nicolai E BMC Cancer; 2014 May; 14():356. PubMed ID: 24886519 [TBL] [Abstract][Full Text] [Related]
58. Plasma free serotonin as a marker for early detection of breast cancer recurrence. Fröbe A; Čičin-Šain L; Jones G; Soldič Ž; Lukač J; Bolanča A; Kusič Z Anticancer Res; 2014 Mar; 34(3):1167-9. PubMed ID: 24596355 [TBL] [Abstract][Full Text] [Related]
59. The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer. Pronk LC; Stoter G; van Putten WL; de Wit R J Cancer Res Clin Oncol; 1997; 123(2):128-32. PubMed ID: 9030253 [TBL] [Abstract][Full Text] [Related]
60. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer. Devine PL; Duroux MA; Quin RJ; McGuckin MA; Joy GJ; Ward BG; Pollard CW Breast Cancer Res Treat; 1995 Jun; 34(3):245-51. PubMed ID: 7579489 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]